Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as biaryl compound), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis), and the like.

An imidazoline compound, a mobility control system, a plugging agent for gas channelling, and a method for carbon dioxide flooding. The structure of the imidazoline compound is represented by formula (1), in which R is pentadecyl, heptadecenyl, or heptadecyl. A mobility control system that contains the imidazoline compound can interact with carbon dioxide to form a plugging agent for gas channelling, and thereby attains a plugging effect for carbon dioxide channelling in a carbon dioxide flooding process. ##STR00001##

An imidazoline compound, a mobility control system, a plugging agent for gas channelling, and a method for carbon dioxide flooding. The structure of the imidazoline compound is represented by formula (1), in which R is pentadecyl, heptadecenyl, or heptadecyl. A mobility control system that contains the imidazoline compound can interact with carbon dioxide to form a plugging agent for gas channelling, and thereby attains a plugging effect for carbon dioxide channelling in a carbon dioxide flooding process. ##STR00001##

Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as biaryl compound), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis) and the like.

Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as biaryl compound), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis) and the like.

Compounds and compositions are described which are useful especially for treatment of angiogenesis-related diseases or disorders such as neovascularisation of the eye, age-related macular degeneration, diabetic retinopathy or cancer.

Compounds and compositions are described which are useful especially for treatment of angiogenesis-related diseases or disorders such as neovascularisation of the eye, age-related macular degeneration, diabetic retinopathy or cancer.

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##